Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Vividion Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2013
Status: Acquired
BioCentury | Jan 23, 2025
Management Tracks
New COOs for Vividion, Edgewise
Plus: Pacira names new heads of commercial, CBO and updates from Vib spinout Tanai, Arcus, Kyverna and Alx
BioCentury | May 22, 2024
Management Tracks
FDA vet Singh joining CRDO Precision for Medicine
Plus: de Moerlooze to depart Bavarian and updates from Engitix, Actio and Oruka
BioCentury | May 6, 2024
Product Development
Tale of two WRN inhibitors: a covalent and a non-covalent molecule enter the clinic
As the first two programs targeting the helicase WRN enter the clinic for MSI+ cancers, they set up a comparison of different inhibitory mechanisms
BioCentury | May 2, 2024
Deals
Novartis gains α-emitter, radioligand platform via $1B Mariana takeout
Largest upfront M&A payment for a preclinical biotech in three years
BioCentury | Feb 15, 2024
Emerging Company Profile
BridGene: a pairwise approach to chemoproteomics for hard targets
The California company’s IMTAC screening platform for hard-to-drug targets has found partners in Takeda and Galapagos
BioCentury | Oct 10, 2023
Emerging Company Profile
Hyku: tapping new targets by taking chemoproteomics beyond cysteine
In co-leading Hyku’s $56M seed round, RA Capital added to its portfolio of chemoproteomics companies
BioCentury | Sep 8, 2023
Management Tracks
CRISPR CEO Kulkarni named chair as Novak departs
Plus: updates from Vividion, Rapport, One Biosciences, enGene, Anokion and more
BioCentury | Mar 23, 2023
Management Tracks
Treco to succeed Bolte as CEO of Inozyme
Plus: Seagen’s Siegall to be CEO at Morphimmune and updates from Jasper, Vividion and more
BioCentury | Jan 4, 2023
Emerging Company Profile
Versant-backed Belharra: light-based chemoproteomics for all amino acids
Scripps spinout launches with $50M series A, $80M up front deal with Genentech to chase difficult targets
BioCentury | Oct 14, 2022
Emerging Company Profile
Matchpoint: a toolkit to create covalent therapies for immunology
Chemoproteomics, machine-learning start-up has $100M from investors including Atlas, Access Biotechnology and Sanofi Ventures
Items per page:
1 - 10 of 49